A Bayesian decision-theoretic design for simultaneous biomarker-based subgroup selection and efficacy evaluation.

Wang, Zheyu; Wang, Fujun; Wang, Chenguang; Zhang, Jianliang; Wang, Hao; Shi, Li; Tang, Zhuojun; Rosner, Gary L

Wang, Zheyu; Wang, Fujun; Wang, Chenguang; Zhang, Jianliang; Wang, Hao; Shi, Li; Tang, Zhuojun; Rosner, Gary L.

Afiliación

Wang Z; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.
Wang F; AstraZeneca.
Wang C; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.
Zhang J; AstraZeneca.
Wang H; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.
Shi L; Alpha Biometrics consulting.
Tang Z; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.
Rosner GL; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.

Stat Biopharm Res ; 14(4): 568-579, 2022.

Article en En | MEDLINE | ID: mdl-37197312

Palabras clave

Bayesian decision-theoretic; Biomarker; Phase II trial; Subgroup selection; Two-stage design

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Qualitative_research Idioma: En Revista: Stat Biopharm Res Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google